Our group (Dejosez et al, 2000) and others (Ashkenazi et al, 1999; Pawlowski et al, 2000; Oya et al, 2001) also observed responsiveness to TRAIL-mediated apoptosis in some RCC cell lines, raising the possibility that TRAIL, either alone or in combination with other therapeutic strategies, might become a cancer therapeutic for otherwise unresponsive RCCs. This evidence concerns the gene TNFSF10 and cancer.